Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00097877
Other study ID # BIASP-2191
Secondary ID
Status Completed
Phase Phase 3
First received November 30, 2004
Last updated January 10, 2017
Start date January 2005
Est. completion date November 2006

Study information

Verified date January 2017
Source Novo Nordisk A/S
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This trial is conducted in the United States of America (USA). The purpose of this study is to test whether Biphasic Insulin Aspart 70/30 twice a day with Metformin improves glycemic control vs. once daily Insulin Glargine with Metformin in subjects with Type 2 Diabetes who are inadequately controlled on basal insulin plus oral anti-diabetic therapy.


Recruitment information / eligibility

Status Completed
Enrollment 293
Est. completion date November 2006
Est. primary completion date November 2006
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Type 2 Diabetes

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
biphasic insulin aspart

insulin glargine


Locations

Country Name City State
Puerto Rico Novo Nordisk Investigational Site Manati
Puerto Rico Novo Nordisk Investigational Site Santurce
United States Novo Nordisk Investigational Site Arlington Texas
United States Novo Nordisk Investigational Site Atlanta Georgia
United States Novo Nordisk Investigational Site Atlanta Georgia
United States Novo Nordisk Investigational Site Aventura Florida
United States Novo Nordisk Investigational Site Baltimore Maryland
United States Novo Nordisk Investigational Site Baton Rouge Louisiana
United States Novo Nordisk Investigational Site Bellevue Washington
United States Novo Nordisk Investigational Site Birmingham Alabama
United States Novo Nordisk Investigational Site Boise Idaho
United States Novo Nordisk Investigational Site Cherry Hill New Jersey
United States Novo Nordisk Investigational Site Chesterfield Missouri
United States Novo Nordisk Investigational Site Chicago Illinois
United States Novo Nordisk Investigational Site Chiefland Florida
United States Novo Nordisk Investigational Site Chula Vista California
United States Novo Nordisk Investigational Site Clinton Oklahoma
United States Novo Nordisk Investigational Site Dallas Texas
United States Novo Nordisk Investigational Site Dallas Texas
United States Novo Nordisk Investigational Site Dallas Texas
United States Novo Nordisk Investigational Site Dallas Texas
United States Novo Nordisk Investigational Site Dallas Texas
United States Novo Nordisk Investigational Site Dayton Ohio
United States Novo Nordisk Investigational Site Dayton Ohio
United States Novo Nordisk Investigational Site Des Moines Iowa
United States Novo Nordisk Investigational Site Eugene Oregon
United States Novo Nordisk Investigational Site Fort Myers Florida
United States Novo Nordisk Investigational Site Fullerton California
United States Novo Nordisk Investigational Site Greensboro North Carolina
United States Novo Nordisk Investigational Site Greer South Carolina
United States Novo Nordisk Investigational Site Houston Texas
United States Novo Nordisk Investigational Site Jacksonville Florida
United States Novo Nordisk Investigational Site Kettering Ohio
United States Novo Nordisk Investigational Site Lancaster Pennsylvania
United States Novo Nordisk Investigational Site Las Vegas Nevada
United States Novo Nordisk Investigational Site Lawrenceville New Jersey
United States Novo Nordisk Investigational Site Lewisville Texas
United States Novo Nordisk Investigational Site Melbourne Florida
United States Novo Nordisk Investigational Site Melrose Park Pennsylvania
United States Novo Nordisk Investigational Site Memphis Tennessee
United States Novo Nordisk Investigational Site Midland Texas
United States Novo Nordisk Investigational Site Milwaukee Wisconsin
United States Novo Nordisk Investigational Site New Albany Indiana
United States Novo Nordisk Investigational Site New Britain Connecticut
United States Novo Nordisk Investigational Site New Hyde Park New York
United States Novo Nordisk Investigational Site Newport News Virginia
United States Novo Nordisk Investigational Site Norristown Pennsylvania
United States Novo Nordisk Investigational Site Ocala Florida
United States Novo Nordisk Investigational Site Ogden Utah
United States Novo Nordisk Investigational Site Omaha Nebraska
United States Novo Nordisk Investigational Site Orange California
United States Novo Nordisk Investigational Site Orange California
United States Novo Nordisk Investigational Site Overland Park Kansas
United States Novo Nordisk Investigational Site Plainsboro New Jersey
United States Novo Nordisk Investigational Site Plano Texas
United States Novo Nordisk Investigational Site Plano Texas
United States Novo Nordisk Investigational Site Plantation Florida
United States Novo Nordisk Investigational Site Portland Oregon
United States Novo Nordisk Investigational Site Richmond Virginia
United States Novo Nordisk Investigational Site Salem Oregon
United States Novo Nordisk Investigational Site San Antonio Texas
United States Novo Nordisk Investigational Site Searcy Arkansas
United States Novo Nordisk Investigational Site Springfield Massachusetts
United States Novo Nordisk Investigational Site St. Louis Missouri
United States Novo Nordisk Investigational Site St. Louis Missouri
United States Novo Nordisk Investigational Site Staten Island New York
United States Novo Nordisk Investigational Site Syracuse New York
United States Novo Nordisk Investigational Site Topeka Kansas
United States Novo Nordisk Investigational Site Tulsa Oklahoma
United States Novo Nordisk Investigational Site Tuscaloosa Alabama
United States Novo Nordisk Investigational Site Vestavia Alabama
United States Novo Nordisk Investigational Site Warrenton Virginia
United States Novo Nordisk Investigational Site West Reading Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Novo Nordisk A/S

Countries where clinical trial is conducted

United States,  Puerto Rico, 

References & Publications (3)

Ligthelm RJ, Gylvin T, DeLuzio T, Raskin P. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-la — View Citation

Oyer DS, Shepherd MD, Coulter FC, Bhargava A, Deluzio AJ, Chu PL, Trippe BS; Initiateplus Study Group.. Efficacy and tolerability of self-titrated biphasic insulin aspart 70/30 in patients aged >65 years with type 2 diabetes: an exploratory post hoc suban — View Citation

Trippe BS, Shepherd MD, Coulter FC, Bhargava A, Brett J, Chu PL, Oyer DS. Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial). Curr Med Res Opin. 2012 Jul;28(7):1203-11. doi: — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary HbA1c After 24 weeks No
Secondary safety variables No
Secondary 8-point plasma glucose profile No
Secondary other glycemic variables No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2